Company research
BridgeBio Oncology Therapeutics, Inc.
CIK 1869105Updated Sep 29, 2026
SecurityBBOT · NASDAQ · equity
Name history
Helix Acquisition Corp. II · through Aug 6, 2025
BBOT price & chart
Loading TradingView…
NASDAQ:BBOT on TradingView ↗About the company
Helix Acquisition Corp. II (Nasdaq: HLXB) is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Helix Acquisition Corp. II raised $184 million in its initial public offering on February 9, 2024. Helix is sponsored by affiliates of Cormorant Asset Management and is headquartered in Boston, Massachusetts.
In the news
BBOT to Participate in Upcoming Investor Healthcare Conferences ↗
Recent filings
4 filing
EFFECT filing
EFFECT filing
Other Events
Items 8.01, 9.01
S-3 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 448,381,000Source | 194,424,196Source | 332,894Source |
| Property, Plant and Equipment, NetUSD | 956,000Source | — | — |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 373,687,000Source | — | — |
| Assets, CurrentUSD | 432,396,000Source | 1,949,777Source | — |
| Prepaid Expense and Other Assets, CurrentUSD | 6,550,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 2,330,000Source | — | — |
| Other Assets, NoncurrentUSD | 12,567,000Source | — | — |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 37,285,000Source | 5,707,515Source | 396,463Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 8,000Source | — | — |
| Additional Paid in CapitalUSD | 767,639,000Source | — | 24,540Source |
| Retained Earnings (Accumulated Deficit)USD | -356,567,000Source | -3,733,121Source | -88,569Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 16,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 411,096,000Source | -3,732,610Source | -63,569Source |
| Liabilities and EquityUSD | 448,381,000Source | 194,424,196Source | 332,894Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 35,041,000Source | 187,515Source | 396,463Source |
| Operating Lease, Liability, CurrentUSD | 522,000Source | — | — |
| Accounts Payable, CurrentUSD | 1,374,000Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | 2,244,000Source | — | — |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | — | 119,706Source | 15,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 425,500,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | 700,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,873,000Source | 271,572Source |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts PayableUSD | -1,840,000Source | — |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -113,894,000Source | -763,820Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 73,328,000Source | -184,000,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 606,000Source | — |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 383,402,000Source | 186,461,597Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 373,819,000Source | 1,697,777Source |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 5,873,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 425,500,000Source | — |
| DepreciationUSD | 280,000Source | — |
| General and Administrative ExpenseUSD | 24,620,000Source | 584,389Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Investment Income, InterestUSD | — | 8,449,291Source |
| Marketable Securities, Unrealized Gain (Loss)USD | -332,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -134,044,000Source | 7,599,512Source |
| Nonoperating Income (Expense)USD | 11,775,000Source | 8,183,901Source |
| Operating ExpensesUSD | 145,819,000Source | — |
| Other Nonoperating Income (Expense)USD | -35,000Source | — |
| Proceeds from Issuance of Common StockUSD | 112,300,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 45,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Operating Income (Loss)USD | -145,819,000Source | -584,389Source |
| Other Nonoperating Income (Expense)USD | -35,000Source | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -134,044,000Source | 7,599,512Source |
| Earnings Per Share, BasicUSD per share | -4.3Source | — |
| Earnings Per Share, DilutedUSD per share | -4.3Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 31,144,775Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 31,144,775Source | — |
| Additional Financial Items | ||
| Current Income Tax Expense (Benefit)USD | 0Source | — |
| General and Administrative ExpenseUSD | 24,620,000Source | 584,389Source |
| Interest Income, OperatingUSD | 11,343,000Source | — |
| Investment Income, InterestUSD | — | 8,449,291Source |
| Nonoperating Income (Expense)USD | 11,775,000Source | 8,183,901Source |
| Operating ExpensesUSD | 145,819,000Source | — |
| Research and Development ExpenseUSD | 121,199,000Source | — |
Offerings
Registration 333-289940
Filing attachments
d97546dex991.htm · 8-K · 2026-09-08
EX-99.1 2 d97546dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients BBO-8520 monotherapy continues to show highly competitive ORR in the 2L+ KRASG12C inhibitor-naïve NSCLC with ORR o…
Read attachment ↗d97546dex992.htm · 8-K · 2026-09-08
EX-99.2 3 d97546dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Corporate Update September 2026 BBOT Next-Generation RAS-Pathway Therapeutics Forward-Looking Statements ThispresentationisbeingmadebyBridgeBioOncologyTherapeutics, Inc.(“BBOT”orthe“Company”).Certainstatementsincludedinthispresentationthatarenothistoricalfactsareforward-lookingstatements. Forward-lookingstatementsgenerallyareaccompaniedbywordssuchas“believe,”“may,”“will,”“estimate,”“continue,”“anticipate,”“intend,”“expect,”“should,”“…
Read attachment ↗bbot-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 bbot-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress • Continued to advance monotherapy and combination cohorts for all clinical programs • Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203 • Presented preclinical data at AACR highlighting the potency and activity of BBO-11818 in KRAS mutant tumor mo…
Read attachment ↗bbot-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 bbot-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress • Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs • Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor • Clinical readouts expected in the second half of 2026 across all three programs • Cash runway expe…
Read attachment ↗d253464dex991.htm · 8-K · 2026-04-23
EX-99.1 2 d253464dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development experience and scientific/business acumen to bear as the company’s top…
Read attachment ↗bbot-ex99_1.htm · 8-K · 2026-03-05
Exhibit 99.1 BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress • BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway. • Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520’s differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a …
Read attachment ↗